Alan Go to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Alan Go has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
2.514
-
Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations. Circ Cardiovasc Qual Outcomes. 2020 09; 13(9):e006415.
Score: 0.702
-
Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI. Clin J Am Soc Nephrol. 2020 01 07; 15(1):26-34.
Score: 0.668
-
Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. J Am Geriatr Soc. 2017 Dec; 65(12):2610-2618.
Score: 0.570
-
Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med. 2006 Feb 21; 144(4):229-38.
Score: 0.256
-
Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477.
Score: 0.202
-
Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy. Pharmacoepidemiol Drug Saf. 2021 12; 30(12):1630-1634.
Score: 0.047
-
Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001 Sep; 7(3):221-8.
Score: 0.047
-
Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes. 2010 May; 3(3):303-8.
Score: 0.021